NATCO PHARMA LIMITED (INDIA)
“Daclatasvir” is the Drug / Molecule content in “Natdac”. Daclatasvir is used for the treatment of patients with chronic Hepatitis C virus (HCV). Daclatasvir inhibits the Hepatitis C Virus (HCV) nonstructural protein; by targeting two steps of the viral replication process, enabling rapid decline of HCV RNA.
Daclatasvir is used for treatment of patients with chronic Hepatitis C .
SIDE EFFECTS :
- Serious risk of bradycardia when Daclatasvir is used with Sofosbuvir and Amiodarone.
- Common side effects include: Headache, Hemolytic Anemia, Nausea, Fatigue, Diarrhea.
- Some common drugs that are strong CYP3A inducers include Dexamethasone, Phenytoin, Carbamazepine, Rifampin,
- When taking Daclatasvir with Non-nucleoside reverse transcriptase inhibitors, the dose of Daclatasvir is increased to overcome CYP3A induction.
- The dose for Daclatasvir should be lowered when taking with antifungals, such as Ketoconazole.
- Concurrent use with Amiodarone, Sofosbuvir and Daclatasvir has may result in an increased risk for serious slowing of the heart rate.
- Do not use more than prescribed dose.
- If you suspect you may have overdosed, call your healthcare provider.
- Do not take extra dose to make up for the missed dose.
- Cases of severe bradycardia and heart block have been observed when used in combination with sofosbuvir with or without other drugs that lower heart rate.
- Daclatasvir should not be used during pregnancy or in women of childbearing potential not using contraception.
Updated On Oct 17, 2019 by Admin
30 mg & 60 mg
1 X 28 Tablets (Plastic Container)
Store at room Temperature , protected from sunlight.